Key facts
- ScreenIn3D’s last known valuation is $3.8M (Jun 2025).
- It has raised $1.3M; the latest was Seed Round ($1.0M) in Jun 2025.
- Notable investors include Innovate UK, Scottish Enterprise, Nidobirds Ventures, University of Strathclyde Endowment, Gabriel Investment Syndicate — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for ScreenIn3D
- ·The full record, as it builds
Funding rounds
No funding rounds for ScreenIn3D are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ScreenIn3D
Developer of advanced drug screening technologies and software designed to de-risk drug discovery. The company leverages microfluidic technology to generate physiologically relevant three-dimensional models of human disease, enabling pharmaceutical and biotechnology professionals to conduct throughput drug screening, reduce costs, and accelerate the drug discovery process using predictive, animal-free disease models.
- Sector
- Healthcare
- HQ
- Glasgow, United Kingdom
- Founded
- 2018
- Employees
- 7
- Website
- screenin3d.com/
- Ownership
- Privately Held (backing)
ScreenIn3D doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ScreenIn3D shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ScreenIn3D in its N-PORT filings yet. We sweep new filings monthly.